Johnson & Johnson $JNJ Shares Bought by Biondo Investment Advisors LLC

Biondo Investment Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 61,362 shares of the company’s stock after purchasing an additional 2,688 shares during the period. Johnson & Johnson makes up about 1.4% of Biondo Investment Advisors LLC’s holdings, making the stock its 29th largest position. Biondo Investment Advisors LLC’s holdings in Johnson & Johnson were worth $10,176,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Elios Financial Group Inc. boosted its position in shares of Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC boosted its position in shares of Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after buying an additional 67 shares in the last quarter. MBA Advisors LLC boosted its position in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after buying an additional 68 shares in the last quarter. Sovereign Financial Group Inc. boosted its position in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after buying an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc boosted its position in shares of Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock worth $767,000 after buying an additional 69 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.1%

NYSE JNJ opened at $179.0980 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a 50-day moving average of $163.48 and a 200-day moving average of $159.23. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $431.33 billion, a P/E ratio of 19.15, a P/E/G ratio of 2.28 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the company posted $2.82 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on JNJ shares. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Citigroup boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.